Your session is about to expire
← Back to Search
Group 2 (Low Dose, Standard Corticosteroid) for Retinitis Pigmentosa
Study Summary
This trial will test the safety of AGTC-501 in people with X-linked retinitis pigmentosa who have already received a gene therapy treatment for the condition.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there currently open spots for participants in this ongoing clinical trial?
"Data from clinicaltrials.gov indicates that recruitment for this particular clinical trial has concluded. Originally published on November 14, 2023, and last updated on February 16, 2024. Despite the cessation of recruitment for this study, there are currently 51 other trials actively enrolling participants."
Are numerous medical facilities within the United States conducting this specific clinical study?
"The trial is operational at 7 diverse sites, including Portland, Miami, and Boston. Selecting a nearby facility can reduce travel commitments for participants entering the study."
What is the level of safety associated with Group 2 (Low Dose, Standard Corticosteroid) for individuals participating in the study?
"Regarding Group 2 (Low Dose, Standard Corticosteroid), our team has rated its safety at a level of 2 on the scale from 1 to 3. This assessment is based on preliminary safety data as this trial is classified as Phase 2 with no efficacy data available yet."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger